أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rizatriptan benzoate, quantity: 7.265 mg (equivalent: rizatriptan, qty 5 mg) - tablet, orally disintegrating - excipient ingredients: magnesium stearate; calcium silicate; aspartame; colloidal anhydrous silica; microcrystalline cellulose; mannitol; crospovidone; flavour - rizatriptan-medis is indicated for the acute treatment of migraine attacks with or without aura.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rizatriptan benzoate, quantity: 14.53 mg (equivalent: rizatriptan, qty 10 mg) - tablet, orally disintegrating - excipient ingredients: aspartame; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; magnesium stearate; mannitol; calcium silicate; flavour - rizatriptan-medis is indicated for the acute treatment of migraine attacks with or without aura.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

bryant ranch prepack - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - ri zatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. limitations of use • rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. • rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see contraindications (4)]. • rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. • safety and effectiveness of rizatriptan benzoate tablets have not been established for cluster headache. rizatriptan benzoate tablets are contraindicated in patients with: • ischemic coronary artery disease (angina pectoris, history of myocardial infarction,

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rizatriptan benzoate, quantity: 7.265 mg (equivalent: rizatriptan, qty 5 mg) - tablet, orally disintegrating - excipient ingredients: calcium silicate; magnesium stearate; mannitol; aspartame; crospovidone; microcrystalline cellulose; colloidal anhydrous silica; flavour - rizatriptan actavis is indicated for the acute treatment of migraine attacks with or without aura.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rizatriptan benzoate, quantity: 14.53 mg (equivalent: rizatriptan, qty 10 mg) - tablet, orally disintegrating - excipient ingredients: magnesium stearate; mannitol; calcium silicate; crospovidone; colloidal anhydrous silica; aspartame; microcrystalline cellulose; flavour - rizatriptan actavis is indicated for the acute treatment of migraine attacks with or without aura.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan 10 mg

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

stat rx usa llc - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan benzoate 5 mg - maxalt is indicated for the acute treatment of migraine attacks with or without aura in adults. maxalt is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications). safety and effectiveness of maxalt have not been established for cluster headache, which is present in an older, predominantly male population. maxalt should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including prinzmetal’s variant angina, or other significant underlying cardiovascular disease (see warnings). because maxalt may increase blood pressure, it should not be given to patients with uncontrolled hypertension (see warnings). maxalt should not be used within 24 hours of treatment with another 5-ht1 agonist, or an ergotamine-containing or ergot-type

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

rebel distributors corp - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan benzoate 10 mg - maxalt is indicated for the acute treatment of migraine attacks with or without aura in adults. maxalt is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications). safety and effectiveness of maxalt have not been established for cluster headache, which is present in an older, predominantly male population. maxalt should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including prinzmetal’s variant angina, or other significant underlying cardiovascular disease (see warnings). because maxalt may increase blood pressure, it should not be given to patients with uncontrolled hypertension (see warnings). maxalt should not be used within 24 hours of treatment with another 5-ht1 agonist, or an ergotamine-containing or ergot-type

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rizatriptan benzoate, quantity: 7.265 mg (equivalent: rizatriptan, qty 5 mg) - tablet, orally disintegrating - excipient ingredients: sucralose; magnesium stearate; mannitol; crospovidone; microcrystalline cellulose; flavour - rizatriptan is indicated for the acute treatment of migraine attacks with or without aura.

كندا - الإنجليزية - Health Canada

mylan pharmaceuticals ulc - rizatriptan (rizatriptan benzoate) - tablet (orally disintegrating) - 5mg - rizatriptan (rizatriptan benzoate) 5mg - selective serotonin agonists